Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid
- PMID: 21367992
- PMCID: PMC3122636
- DOI: 10.1128/JCM.00084-11
Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid
Abstract
CXCL13 in cerebrospinal fluid (CSF) could be an important component for diagnosing Lyme neuroborreliosis (LNB). Levels of intrathecal CXCL13 were determined for 58 LNB patients and 210 controls; sensitivity was 88% and specificity was 89% (cutoff, 250 pg of CXCL13/ml of CSF). Elevated levels of CXCL13 can aid in the diagnosis of LNB, but levels should be interpreted with care.
Figures
References
-
- Blanc F., et al. 2007. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology 69:953–958 - PubMed
-
- Cagigi A., et al. 2008. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood 112:4401–4410 - PubMed
-
- Ljøstad U., Mygland A. 2008. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J. Neurol. 255:732–737 - PubMed
-
- Mygland A., et al. 2010. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur. J. Neurol. 17:8–16 - PubMed
-
- Rupprecht T. A., Koedel U., Angele B., Fingerle V., Pfister H. W. 2006. Cytokine CXCL13—a possible early CSF marker for neuroborreliosis. Nervenarzt 77:470–473 (In German.) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
